Amneal Pharmaceuticals, Inc. Balance Sheet
AMRX / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 10 fiscal years. All figures from audited SEC 10-K filings.
Amneal Pharmaceuticals, Inc. had $3.7B in total assets with negative shareholders' equity of $71M as of FY2025. Total debt was $2.6B against $282M in cash, resulting in $2.3B net debt.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $282.0M | $110.6M | $26.0M | $26.0M | $341.4M | $151.2M | $213.4M | $74.2M | $74.2M | $27.4M |
| Accounts Receivable | - | - | - | $741.8M | $662.6M | $638.9M | $604.4M | $481.5M | $351.4M | - |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M | $490.6M | $381.1M | $457.2M | $284.0M | - |
| Current Assets | $1.9B | $1.6B | $1.4B | $1.4B | $1.5B | $1.6B | $1.2B | $1.3B | $771.9M | - |
| PP&E (Net) | $442.9M | $424.9M | $447.6M | $469.8M | $514.2M | $477.8M | $478.0M | $544.1M | $486.8M | - |
| Goodwill | $595.5M | $597.4M | $598.9M | $598.9M | $522.8M | $419.5M | $426.2M | $26.4M | $26.4M | $28.4M |
| Total Assets | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B | $4.0B | $3.7B | $4.4B | $1.3B | - |
| Current Liabilities | $881.6M | $1.1B | $846.6M | $752.8M | $677.2M | $676.9M | $550.4M | $553.9M | $296.9M | - |
| Total Debt | $2.6B | $2.4B | $2.4B | $2.6B | $2.7B | $2.8B | $2.6B | $2.7B | $1.4B | - |
| Shareholders' Equity | -$70.8M | -$109.3M | $19.8M | $298.4M | $360.3M | $303.3M | $232.0M | $504.8M | $0 | - |